Abiopharma

🔍 Rodino-Klapac Louise (Executive)

Company: Sarepta Therapeutics, Inc. (SRPT)

Report Date: 2025-09-03

Detailed Transactions and Holdings:

• Acquired 93,875 shares of Common Stock (Direct)
  Date: 2025-09-03 | Code: A | equity_swap_involved: false | shares_owned_after: 178,612.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 50,000 shares of Common Stock (Direct)
  Date: 2025-09-03 | Code: A | equity_swap_involved: false | shares_owned_after: 228,612.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 50% of the RSUs will vest on September 3, 2026, and the remaining 50% will vest on September 3, 2027, subject to the Reporting Person's continued service to the Company.
• F2: Includes 106 shares of common stock purchased on August 31, 2025 through the Company's Employee Stock Purchase Plan
• F3: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 100% of the RSUs will vest on September 3, 2028, subject to the Reporting Person's continued service to the Company and only if certain performance criteria has been deemed achieved by the Compensation Committee of the Board.